• SynAct Pharma published a medical research company presentation outlining development plans for resomelagon (AP1189), an oral pro-resolution immunology drug candidate.
• Positioned as Phase 3-ready in rheumatoid arthritis, targeting first-line add-on use intended to delay biologics or JAK inhibitors.
• Presentation cites a SEK 100 million financing in July 2026 to fund Phase 3 readiness.
• Pipeline update highlights Phase 2a infectious-disease studies, including dengue initial data in Q4 2026; severe respiratory infection data due mid 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. SynAct Pharma AB published the original content used to generate this news brief on September 08, 2026, and is solely responsible for the information contained therein.